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ABSTRACT 
Objective: The aim of present research was to develop compression coated tablet for pulsatile drug delivery of Acebrophylline used for chronotherapy of 
asthma. The drug delivery system was designed to deliver the drug at such a time when it could be most needful to patient of asthma. 
Methods: The compression coated tablets containing Acebrophylline in the inner core were formulated by direct compression method with an 
outer coating of different amounts of HPMC K4M. 
Results: The release profile of press coated tablet exhibited a lag time depending upon the amount of HPMC K4M in compression coating, followed 
by burst release. Optimization was done using 32
Conclusion: The chronodelivery of Acebrophylline was achieved by formulating the tablet by compression coating technique. 
 factorial design considering two independent factors at three levels. Data was evaluated 
statistically by Stat Ease Design Expert 7.0.0 software. The optimized batch F6 gave a lag time of 6 hr and drug release of 94% in which the 
concentration of HPMC K4M is 40% and the concentration of SSG is 2.5 %. 
Keywords: Compression coated tablet, Lag time, Chronotherapy, Acebrophylline, Asthma. 
 
INTRODUCTION 
In the last several decades has to be seen the development of many 
controlled-release formulation having the constant drug release 
rates to maintain the concentration of drug in the human body, apart 
from the patient’s physiological condition. However, the long-term 
constant concentration of drug in the human blood and tissue can be 
the source of problem like tolerability, resistance, and drug side [1]. 
People are different significantly in their physiological and 
biochemical condition during any 24 hr period, because of circadian 
rhythm, and as a result the constant drug delivery into the body 
seems both needless and unwanted. If the drug release profile 
mimics a living system's pulsatile hormone secretion, then it may 
improve drug’s effectiveness, and reduce the toxicity of a specific 
drug administration schedule.  
The medication and treatments provided according to the human 
body's circadian rhythms will result in better outcomes [2]. This can 
be provided by a chronopharmaceutical dosage regimen with 
pulsatile release which matches the circadian rhythm resulting from 
a disease state, so optimizing the therapeutic effect while 
minimizing side effects [3]. The compression coating technique is a 
simple and distinctive technology used to provide tablets with a 
programmable lag phase, followed by a rapid, or rate-controlled, 
drug release after administration. This technique has many 
advantages, and there is no special coating solvent or coating 
equipment is required for manufacturing this type of tablet. Pulsatile 
drug delivery systems (PDDS) are ahead importance because these 
systems deliver the drug at particular time as per the 
pathophysiological need of the disease, resulting in better patient 
therapeutic efficacy and compliance [4, 5]. Diseases in which PDDS 
are promising include cardiovascular diseases, asthma, arthritis, 
hypercholesterolemia, and peptic ulcer. The pathophysiology of 
arthritis and patients with osteoarthritis tend to have less pain in 
the morning and more at night; while those with rheumatoid 
arthritis, have pain that usually peaks in the morning and decreases 
throughout the day [6, 7]. 
Compression-coating presents an attractive alternative to spray-
coating techniques for high molecular weight polymers. Thick 
coatings can be applied rapidly and it is a solvent-free coating 
Process [8]. 
Compression-coating has been used in the pharmaceutical field for 
different purposes:  
(1) To protect hygroscopic, light-sensitive, oxygen-labile or acid-
labile drugs [9]. 
(2) To combine and separate different therapeutic drugs [10, 11]. 
(3) To modify a drug release pattern (delayed, pulsatile and 
programmable release of different drugs in one tablet) [12, 13].  
Various materials have been investigated as compression coatings to 
obtain time-controlled release: HPMC [14, 15, 16] hydroxypropyl 
cellulose [17], polyethylene oxide [18], micronized ethyl cellulose 
[17], Eudragit RS [18], behenic acid [19]. Bimodal drug release 
usually obtained with multilayered matrix tablets [20] can also be 
obtained with compression-coated tablets [21, 22]. The purpose of 
this study was to develop time-release compression coated tablet 
containing acebrophylline for chronotherapy of asthma. The oral 
press coated tablet was developed to achieve the time-controlled 
disintegrating or rupturing function with a distinct predetermined 
lag time. The HPMC-compression-coating resulted in release profiles 
with a distinct lag time depending on the amount of HPMC in 
compression coating. Burst release was obtained by incorporating a 
super disintegrant (SSG) within the core tablet. 
MATERIALS AND METHODS 
Materials 
Acebrophylline was obtained as a gift sample from Kores India Ltd. 
(Mumbai, India.) Sodium Starch Glycolate (SSG), magnesium 
stearate microcrystalline cellulose (MCC) and Ludipress (directly 
compressible lactose) were obtained as gift samples from 
Wockhardt Ltd. (Aurangabad, India.) HPMC K4M was obtained from 
Colorcon Asia Pvt. Ltd. (Goa) as a gift sample. 
Methods 
Fourier Transform Infrared (FTIR) spectroscopy 
The FTIR spectrum was recorded using Prestige-21 (SHIMADZU) 
with IR resolution software. The procedure consisted of, placing a 
drug sample in FTIR cuvette. The drug sample was placed in the 
light path and scanned over the range of 4000-400 cm-1 on Shimadzu 
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FTIR Prestige-21. The obtained spectrum was recorded and 
analyzed. 
Drug-excipients compatibility study 
The Drug-excipients compatibility study was carried by DSC with 
their physical mixture in ratio 1:1. The mixtures were prepared by 
triturating the drug with excipients and the mixtures were stored for 
24 hours at room temperature. The mixtures were then filled in 
aluminum pan specially made for DSC sampling and the DSC 
thermogram was recorded. 
Drug solubility study 
The drug solubility study was carried in water and different buffer 
solutions with pH 1.2, 6.8 and 7.4. The excess amount of drug was 
added in the buffer solution to make saturated solution.  
Then saturated drug solutions were sonicated thrice, each time for 
10 min. The solutions of Acebrophylline were kept overnight for 
attainment of equilibrium with solvent. Prepared solutions were 
filtered using Whatman filter paper no 42. The filtrate was analyzed 
spectrophotometrically. 
Characterization of blend of API and excipients 
The drug (Acebrophylline), microcrystalline cellulose (MCC) and 
superdisintegrant (Sodium Starch Glycolate) were thoroughly 
blended for 20 min. Later on magnesium stearate was added and 
again blended for 2 min. The blend was evaluated for Angle of 
repose, Hausner’s ratio, Bulk density, Tapped density, Carr’s index, 
and similar evaluation was done for the blend of outer coating 
material. 
Formulation of RRCTSs 
RRCTS were prepared by direct compression method as per the 
formula given in Table 9. The ingredients (Acebrophylline, MCC and 
SSG) were accurately weighed and mixed in geometric proportion. 
The mixture was blended for 20 min in a sealable polythene bag. 
Then magnesium stearate was weighed and added to the mixture 
and again blended for 2 min.  The resulting uniform blend was 
compressed to form the tablets using the 8 mm, circular, flat faced 
punch on 12 station Labpress compression machine. The total 
weight of tablets was kept constant at 200 mg. The tablet press 
setting was kept constant across all formulations. 
  
Table 1: Formulation composition for factorial batches 
Tablet ingredient(mg) Factorial batches 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Core tablet 
Acebrophylline 100 100 100 100 100 100 100 100 100 
SSG 3 4 5 3 4 5 3 4 5 
MCC 95 94 93 95 94 93 95 94 93 
Magnesium stearate 2 2 2 2 2 2 2 2 2 
Total weight 200 200 200 200 200 200 200 200 200 
Coat 
HPMC K4M 70 70 70 80 80 80 90 90 90 
Ludipress 128 128 128 118 118 118 108 108 108 
Magnesium stearate 2 2 2 2 2 2 2 2 2 
Total weight 200 200 200 200 200 200 200 200 200 
Total weight of PCT 
 400 400 400 400 400 400 400 400 400 
 
Evaluation of RRCTSs 
Physical characterization 
The prepared RRCTSs were evaluated for the physical 
characteristics such as thickness; diameter, hardness and weight 
variation test according to the Indian Pharmacopoeia (IP) 2007. 
Drug content 
Twenty tablets were taken and powdered. Tablet powder equivalent 
to 25 mg of acebrophylline was weighed, sufficient volume of 
phosphate buffer was added and volume was made upto 100 ml 
with phosphate buffer pH 7.4.  
Then the solution was sonicated for 30 min. and filtered. The filtrate 
(4 ml) was further diluted with phosphate buffer pH 7.4 upto 100 ml 
to get required concentration. The absorbance of resulting solution 
was measured UV spectrophotometer at 273.2 nm. 
In-vitro disintegrating time 
In vitro disintegration time of six tablets from was determined by 
using disintegration test apparatus. To test for disintegration time 1 
tablet was dropped in each glass tube, and the basket rack assembly 
was set in a 1L beaker of water at 37±2°C. 
In-vitro dissolution studies 
The in-vitro dissolution studies were carried out in 0.1N HCl (900 
ml) at 37 ± 0.5o
Formulation of PCTs 
C using USP dissolution apparatus type II. The speed 
of rotation was maintained at 100 rpm. 5 ml samples were 
withdrawn at predetermined time interval and content of 
Acebrophylline was determined by using UV spectrophotometer at 
273.2 nm. 
PCTs were prepared by compression coating of prepared 8 mm 
diameter RRCTSs into 11 mm diameter tablets. The composition of 
batches containing varying amount of HPMC K4M and SSG were as 
shown in Table 1. 
Compression or press coating of the tablets was done by placing half 
amount of the compression coat blend into the die cavity, then 
manually placing the RRCTS on the powder bed centrally.  
Further remaining half quantity of the compression coating material 
was added in the die cavity from above. Then finally the tablet was 
compressed by the tablet compression machine. 
Evaluation of PCTs 
Hardness of PCTs was measured by Monsanto hardness tester and 
thickness by using vernier caliper. The friability of the tablets was 
determined by using Roche friabilator. The % friability was 
calculated by the following formula: 
% F =  �
 W0 − W 
W
�  × 100 
Where, F is friability, WO is the weight of tablets before test, W is 
weight of tablets after test. 
In-vitro dissolution study 
The in vitro dissolution study of press coated tablets was performed by 
using 0.1 N HCl pH 1.2 (acid stage) as dissolution medium for first two 
hours and then remaining time in phosphate buffer pH 7.4 (buffer stage) 
in a USP Type II Paddle Apparatus containing 900 ml of dissolution 
medium maintained at 37±2°C with a speed of 100 rpm. 
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Lag time is the time before the drug release has started or the time 
in which less than 10% of the drug has released. The lag time (t10) 
and release time (t80–10) were defined as the times in hr of 10% 
and 80–10% drug released, respectively. The lag time (hr) for 
different formulations was obtained from the in vitro dissolution 
study of PCTs. 
Water uptake study (% Swelling) 
In this study tablet of each batch was separately placed in the basket 
of dissolution apparatus by using water as immersion medium at 
37±2°C. Tablets were withdrawn at a time interval of 3 hr and 
blotted with tissue paper to remove the excess water.  
The weight of tablet after swelling was measured on an analytical 
balance. The initial and final weights of the tablet were used to 
calculate % swelling or water uptake of the tablet as follows 
% Water uptake =  �
 Wt − W0 
W0
�  × 100 
Where, Wt and W0 are the final weight after swelling and initial dry 
weight of the tablet respectively. 
Transverse and longitudinal section view of press coated 
tablets 
To demonstrate the central positioning of the core tablet within the 
press coated tablet, the core tablet blend was mixed uniformly with 
Erythrosine, a red dye. This was then compressed to produce red 
coloured tablet cores. 
Transverse and longitudinal sections of press coated tablets were 
made using surgical blade in order to verify the position of position 
of core tablet. Figure No. shows the photographs of these sections. 




Fig. 1:  A) Transverse and B) Longitudinal section view of press 
coated tablets 
 
Optimization by 32 factorial design 
A 32 full factorial design was used in the present study. In this design 
2 factors were evaluated each at 3 levels, and experimental trials 
were performed at all 9 possible combinations. The amount of 
release retarding polymer HPMC K4M (X1) and amount of 
superdisintegrant, SSG (X2) were selected as independent variables 
and each factor being studied at -1, 0, +1 level. The % DR (drug 
release) and lag time were considered as the dependant variables. 
Analysis of data by design expert software 
A 32 full factorial design was selected and the 2 factors were 
evaluated at 3 levels, respectively. The statistical treatment and 
interpretation of data was done by Stat Ease Design Expert 7.0.0 
software.  
The analysis of variance (ANOVA) is represented in table (Table 9, 
10). The data were also subjected to 3-D response surface 
methodology to study the interaction of independent variables 
(Figure 4, 5). 
RESULTS AND DISCUSSION 
Fourier Transform Infrared (FTIR) spectroscopy 
FTIR spectrum of acebrophylline was recorded and characteristic 
peaks were observed. 
 
 
Fig. 2: FTIR spectrum of Acebrophylline 
 
The descriptions of the observed peak are given in the following 
table. 
 
Table 2: FT-IR characteristic peaks of Acebrophylline 
S. No. Assignment  wave number cm-1 
(Recorded) 
1 -N-H group 3500.80 
2 -N-H2 group 3446.79 
3 -OH group 3319.49 
4 -C=O Stretch 1700 
5 -COOH group 1700 
 
Drug-excipient compatibility study 
The possible interaction between the drug and the polymers was 
studied by differential scanning calorimeter (DSC). There was no 
considerable change in DSC endothermic values, comparing pure 
Acebrophylline and with the excipients (HPMC K4M, SSG, MCC and 
Ludipress) which indicated the absence of any interaction between 
drug and excipients used in the preparation. Peak value was 
obtained at 215ºC which is very much nearer to pure drug i. e 217 
ºC. DSC thermogram is shown in Figure 3. 
 
 
Fig. 3: DSC thermogram of: A) Acebrophylline B) Acebrophylline 
+ excipients 
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Drug solubility study 
Solubility profile of acebrophylline indicated that the drug is slightly 
soluble in water and methanol and soluble in ethanol.  
Characterization of blend of api and excipients 
The blend of API and excipients was evaluated for parameters like 
Angle of repose, Bulk density, Tapped density, Compressibility index 
and Hausner’s ratio. The results obtained were as shown in Table 3. 
Evaluation of RRCTSs 
The immediate release core tablets were evaluated for weight 
variation test, hardness, thickness, % friability, in vitro 
disintegration time and drug content.  
The weight of all the tablets was found to be within the range, 
hardness was constant and % friability of the tablets was also 
within the acceptable limits. The results obtained were as shown 
in Table 4. 
 
Table 3: Evaluation of precompression parameters 
Batch code Evaluation of parameters 
Angle of repose(°) Bulk density Tapped density Compressibility index (%) Hausner’s ratio Flowability 
F1 28.32 0.281 0.319 15.4 1.12 Good 
F2 29.42 0.285 0.331 13.8 1.11 Good 
F2 27.20 0.350 0.249 15.3 1.17 Good 
F4 29.31 0.260 0.240 12.51 1.15 Good 
F5 28.22 0.264 0.317 14.80 1.14 Good 
F6 27.20 0.319 0.271 13.17 1.16 Good 
F7 28.22 0.218 0.299 15.39 1.21 Good 
F8 29.42 0.270 0.313 15.21 1.19 Good 
F9 29.8 0.281 0.320 14.10 1.11 Good 
 
Table 4: Evaluation of tablets of RRCTSs 







Drug content (%) In vitro DT (Sec) Friability (%) 
F1 200.61 3-3.5 2.76 99.71 34.5 0.396 
F2 200.30 3-3.5 2.75 99.82 33.7 0.383 
F3 200.66 3-3.5 2.76 100.45 33.1 0.410 
F4 200.70 3-3.5 2.75 100.58 31.9 0.371 
F5 200.60 3-3.5 2.77 99.99 30.9 0.381 
F6 200.59 3-3.5 2.78 100.53 30.8 0.355 
F7 200.81 3-3.5 2.76 99.83 29.8 0.452 
F8 200.41 3-3.5 2.75 100.41 28.8 0.310 
F9 200.72 3-3.5 2.72 100.60 28.5 0.351 
The press coated tablets were evaluated for weight variation test, hardness, thickness, % friability and drug content. The results obtained were as 
shown in Table 5. 
 
Table 5: Evaluation of tablets of factorial batches (PCTs) 







Drug content (%) Friability (%) 
F1 400.66±1.18 5.5-6 5.43±0.31 99.72±0.18 0.468±0.23 
F2 400.22±1.26 5.5-6 5.44±0.48 99.81±0.21 0.448±0.15 
F3 401.77±0.94 5.5-6 5.46±0.052 100.45±0.10 0.472±0.36 
F4 399.83±0.78 5.5-6 5.45±0.114 100.58±0.19 0.455±0.18 
F5 400.55±1.14 5.5-6 5.42±0.047 99.97±0.23 0.446±0.22 
F6 400.55±1.24 5.5-6 5.47±0.068 100.53±0.19 0.452±0.27 
F7 400.93±1.27 5.5-6 5.48±0.070 99.93±0.24 0.351±0.37 
F8 400.33±1.29 5.5-6 5.40±0.085 100.41±0.11 0.237±0.28 
F9 400.8±1.08 5.5-6 5.42±0.091 100.60±0.35 0.404±0.41 
Values are mean ± SD, n=3. 
 
Lag Time 
The lag time of the PCTs was measured by determining the time for 
which there is no release or less than 10% release of the drug from 
the dosage form. It was done by in vitro dissolution testing of the 
dosage form. 
From the dissolution profile of PCTs (Table 7 and Figure 4), it is 
evident that the PCTs exhibited a specific lag time which depended 
on the polymer concentration in that batch. The lag time increases as 
the polymer concentration was increased, it was 4 hr for 35% 6 hr 
for 40% and 8hr for 45% HPMC K4M concentration.  
The lag time showed a direct relationship with the amount of HPMC 
K4M in the outer coating. 
Water uptake study (% Swelling) 
A direct correlation between Swelling Index and Lag Time was observed 
from the obtained results. The lag time was found to be increased with 
increasing swelling index. Higher Swelling Indices were observed in 
formulation batches containing higher amount of HPMC K4M. 
This may be due to uptake of water and swelling of the polymer 
which is hydrophilic and forms a gel upon hydration. 
 
 
Table 6: Swelling Index of PCTs 
Batch code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Swelling Index (%) 41.45 42.2 42.88 58.04 57.00 55.85 70.14 72.12 71.09 
  
Table 7: Dissolution profile of RRCTSs 
Time (min) % DR 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
2 30.8 32.13 33.92 46.89 44.96 45.2 54.01 50.9 51.2 
5 53.98 57.21 58.98 64.2 68.8 67.1 73.1 73.9 79 
10 84.01 89.11 90.09 86.11 90.5 86.9 86.4 92.6 96.1 
15 90.12 91.3 95.8 92.2 94.01 97.7 92.4 96.3 98.4 
 
Drug release studies of RRCTSs and PCTs 
The in vitro dissolution of RRCTSs showed more than 80% drug 
release within 10 min. (Table 7 and Figure 4). The maximum drug 
release was obtained from batches having highest amount of 
Superdisintegrant (SSG). The amount of drug released exhibited a 
direct relationship with the amount of SSG in core tablet. 
The graphical representation of the dissolution profile of RRCTSs 
is shown in Figure 4. It was evident that core tablets of all the 
batches showed an immediate release before it was compression 
coated with an outer layer consisting of HPMC K4M and 
Ludipress. The mechanism of action of SSG involves rapid and 
extensive swelling which causes burst release of the drug.  The 
PCTs of different batches showed a variable lag time depending 
on the concentration of HPMC K4M in the outer coating layer. 
The PCTs showed a lag time before the drug release because the 
RRCTSs were completely surrounded by the polymer layer which 
prevented the release of drug from the RRCTSs. Burst release 
after a specific lag time occurred due swelling and erosion of the 
outer hydrophilic polymer layer.  
When the polymer layer swelled adequately, it allowed sufficient 
dissolution medium to enter into it and reach the core tablet. 
The superdisintegrant in the core swelled extensively which 




Fig. 4: % Drug release from RRCTSs 
 
Table 8: Dissolution profile of factorial batches (PCTs) 
Time (hr) % DR 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 0.002 0.006 0.003 0.004 0.005 0.004 0.0031 0.003 0 
2 0.006 0.008 0.006 0.006 0.006 2.66 0.007 0.006 0.002 
3 1.213 3.026 2.198 1.94 1.957 1.95 1.999 1.782 0.005 
4 6.69 8.4 7.17 4.9 4.21 2.8 2.712 3.011 1.821 
5 76 93 86 7.6 7.991 6.4 3.001 3.691 2.712 
6 72.51 90.6 89 8.3 9.38 9.5 4.123 5.91 3.45 
7 78.6 92 86 86.8 89 94 7.421 7.771 4.98 
8    96 96 87.3 9.01 9.81 7.8 
9    92.3 92.5 85.9 79 94.6 88.5 
10    94.2 94 84.8 88.32 95-01 91 
11       87.4 96.48 93 
12       86.21 94.83 95.4 
The graphical representation of the dissolution profile of PCTs is shown in Figure 5. The batches F1-F3, F4-F6 and F7-F9 showed a lag time of 4, 6 
and 8 hr respectively. 
 
Table 9: Analysis of Variance for R1 (lag time) 
Source Sum of Squares Degrees of Freedom (df) Mean Square F Value p- value Prob > F Model 
Model 24.00 5 12.00 6.366E+007 < 0.0001 significant 
A 24.00 1 24.00 6.366E+007 < 0.0001 
B 0.000 1 0.000 6.366E+007 < 0.0001 
Residual 0.000 6 0.000 - - 
Core Total 24.00 8 - - - 
The Model F-value of 63660000.00 implies the model is significant.  
There is only a 0.01% chance that a "Model F-Value" this large could occur due to noise. Values of "Prob > F" less than 0.0500 indicate model terms 
are significant. In this case A, B are significant model terms. Values greater than 0.1000 indicate the model terms are not significant. 
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Table 10: Analysis of Variance for R2 (% DR) 
Source Sum of Squares Degrees of Freedom (df) Mean Square F Value p- value Prob > F Model 
Model 407.84 5 81.57 958.58 0.0001 significant 
A 8.17 1 8.17 95.97 0.0023 
B 395.28 1 395.28 4645.31 0.0001 
Residual 0.26 3 0.085 - - 
Core Total 408.1 8 - - - 
 
Optimization and Analysis of Data by Design Expert Software 
The 32 full factorial design was selected to study the effect of 
independent variables, amount of HPMC K4M (A) and amount of SSG 
(B) on dependent variables lag time and %DR. A statistical model 
incorporating interactive and polynomial terms was utilized to 
evaluate the responses. The optimized batch was suggested by this 
software depending on the required lag time and maximum % drug 
release. ANOVA for the dependent variables, lag time and % DR, was 
shown in Table 9 and 10 respectively. The coefficients of X1 and X2 
were found to be significant at p<0.05, hence confirmed the 
significant effect of both the variables on the selected responses. 
ANOVA and Multiple regression analysis were done using Stat-Ease 
Design Expert 7.0.0 software. 
 
Fig. 5: % Drug released from PCTs 
 
 
Fig. 6: 3D response surface graph for lag time 
 
 
Fig. 7: 3D response surface graph for % DR 
CONCLUSION 
A chronotherapeutic dosage form was formulated by press coating 
technique. The lag time and time-controlled release behavior of 
Acebrophylline from press-coated tablets could be modulated by 
varying the concentration of polymer in outer coating layer and 
thickness of the compression coating. Formulations F4-F6 
compression coated tablets achieve a burst release after 6 hr lag 
time. The dosages should be timed to ensure that the highest blood 
levels of the drug coincide with peak pain. For asthma the optimal 
time for an bronchodilators to be taken is after the evening meal. 
Considering this the preferable lag time would be of 6 hr. All the 
batches formulated showed a pulsatile release pattern of 
Acebrophylline which is suitable for chronotherapy of asthma. 
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